Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug

Summary

Novo Nordisk has licensed a preclinical weekly oral GLP-1/GIP receptor agonist from Hengrui for weight loss treatment with a $300M upfront payment. This marks Novo's fourth weight loss-focused deal of the year.